Special Power of Attorney

for representation in the Ordinary General Meeting of Shareholders of Antibiotice SA on 30.09/01.10.2026

Entity *(company)* ____, head office in ________________________(city), _____________ county, _______________ street no. ___, registered at the Trade Register Office under _________, fiscal code no. ____________________________________, in capacity of holder of (no.)__________ shares amounting to ____________ % of total shares issued by Antibiotice SA and recorded in the Shareholder Register of the Central Depository Bucharest, legally represented by Mr./Ms. ____ identified by National Identification Number _________ ID series ____ no ________ which grant me ____________votes (________ % of total voting rights) in the General Meeting of the Shareholders held on **30.09/01.10.2026**, hereinafter referred to as the **principal,** and Mr./Ms. ____, resident of ___________________, street ________________ no. __, identified by National Identification Number ______________ ID series __ no ________ or in their absence, Mr. / Ms. _________________________________, resident of ______________________, street ______________ no.___, identified by National Identification Number _________ ID series __ no ________ , appointed as **attorney-in-fact.**

I, **the principal,** hereby invest **the attorney-in-fact** with full powers in exerting the voting rights in the name and on behalf of the principal (relative to the shares owned and registered in the Shareholders Register by **17.09.2026** as the reference date), in the OGMS held at Antibiotice HQ on **30.09.2026**, at 10:00 am, and, respectively in the second meeting organized on **01.10.2026** 10:00 am, as per the legal provisions of art. 118 Law 31/1990 republished.

No	Agenda for the Ordinary General Meeting of Shareholders	Option		
		for	against	abstention
0	1	2	3	4
1.	The approval of the Financial Report for the first half of 2026, consisting of: a. simplified half-yearly financial statements; b. half-yearly report of the board of directors; c. the declaration of the responsible persons; d. the full report of the audit firm.			

2.	Approval of the allocation of 50% of the net profit for the 2025 financial year, setting the gross dividend at RON 0.019877174 per share, setting 16 October 2026 as the record date for identifying the shareholders entitled to the effects of this resolution, setting 15 October 2026 as the ex-date, and setting 28 October 2026 as the dividend payment commencement date.			
3.	Approval of the allocation of 90% of the net profit for the 2025 financial year, setting the gross dividend at RON 0.035778913 per share, setting 16 October 2026 as the record date for identifying the shareholders entitled to the effects of this resolution, setting 15 October 2026 as the ex-date, and setting 28 October 2026 as the dividend payment commencement date.			
4.	The ratification of the Management Board's Decision no. 1 of 25.06.2026, regarding: • the approval of the increase in the multicurrency, multiproduct, cash and non-cash credit facility, contracted with UniCredit Bank SA from the amount of RON 91,500,000 to the amount of RON 141,000,000. • the approval/maintenance of the guarantee of the facility mentioned above, in the amount of RON 141,000,000, which will be contracted with UniCredit Bank SA with the following: - Mortgage on the current and future accounts opened by Antibiotice SA at UniCredit Bank SA. • approval of the authorization of Mr. Ioan Nani as General Director to sign on behalf of Antibiotice SA all documents/credit contracts and their accessories, necessary and related to the contracting and implementation of the credit facility in the total amount of RON 141,000,000 from UniCredit Bank SA, as well as all the subsequent additional documents related to the documents/credit contracts and accessories related to this credit.			
5.	The rectification of the Decision no. 3 of the Ordinary General Meeting of Shareholders dated 06.11.2025, in order to remedy a material error, as follows: Resolution No. 3 of the Ordinary General Meeting of Shareholders dated November 6, 2025—stating "With the votes 'for' from shareholders representing 100% of the total votes cast, the vacancy of a director position at Antibiotice S.A. is acknowledged"—is rectified to read: "With the votes 'for' from shareholders representing 100% of the total votes cast, the vacancy of the director position held by Mr. Cătălin-Codruț Popescu is acknowledged, effective as of November 6, 2025."			

I hereby authorize my above mentioned attorney-in-fact to vote according to the way he/she was empowered.

I give him/her discretionary power on the issues that haven’t been identified and included on the agenda by the date of issuing the hereby Power of Attorney.

Yes ☐ No ☐

I hereby attach a copy of the valid registration certificate.

Drafted today, ______________, in three original copies with similar legal power: one for the principal, one for the attorney-in-fact and the third to be recorded at Antibiotice SA Registrar's Office by 28.09.2026, 10:00 am.

Contact phone no. ____

PRINCIPAL (Securities holder),

____

(Name of the entity acting as principal, in capitals)

____

(Last name and first name of the attorney-in-fact, in capitals)

____

(Seal and signature of the attorney-in-fact)

Note:
The Power of Attorney will be modified and completed accordingly if, in accordance with the legislation in force, one or more shareholders representing, individually or together, at least 5% of the share capital will introduce new items on the agenda of the general meeting.
In the event of updating the Power of Attorney form, please check the requirements in the GM Convening Notice starting with the 16th day after the publication of the Convening Notice.
After filling in and signing the special Power-of-Attorney, an original copy shall be submitted/sent to Antibiotice headquarters, in a sealed envelope, mentioning the confidential nature of the content, so that it is recorded at the Antibiotice SA Registrar's Office by 28.09.2026, 10:00 am at the latest.